Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • News
  • Industry
  • Pharma News
  • Ahead of Sitagliptin...

Ahead of Sitagliptin going off-Patent, NPPA moves to fix retail price of its FDC

Meghna A SinghaniaWritten by Meghna A Singhania Published On 2022-04-15T17:22:45+05:30  |  Updated On 15 April 2022 5:22 PM IST
Ahead of Sitagliptin going off-Patent, NPPA moves to fix retail price of its FDC
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

New Delhi: With the popular antidiabetic drug Sitagliptin soon expected to go off-patent, the apex drug price regulator, National Pharmaceutical Pricing Authority (NPPA), has moved swiftly to pass on the benefit to the consumers by fixing the price of its fixed-dose combinations (FDC) with Metformin marketed by various companies. In its first go, the NPPA has decided to fix the price of the FDC made by Alkem, Zydus, Exemed/Emcure, Morepen, but more companies as likely to follow as seventeen applications have been received till now for retail price fixation of four Fixed Dose Combinations (FDCs) of Sitagliptin and Metformin tablets.

Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.

Sitagliptin is a Merck Sharp and Dohme drug that is likely to lose patent in July 2022.

Following the recent meeting the apex price regulator, the retail price of the formulation has been fixed for four Fixed Dose Combinations (FDCs) of Sitagliptin and Metformin tablets which include

(i) Sitagliptin 50 mg + Metformin 500 mg tablet,

(ii) Sitagliptin 50 mg + Metformin 1000 mg tablet,

(iii) Sitagliptin 50 mg + Metformin 850 mg tablet and

(iv) Sitagliptin 100 mg + Metformin 1000 mg (extended release) tablet.

The Multidisciplinary Committee of Experts of the NPPA deliberated on the retail price fixation of the popular diabetes drug from various companies during the Authority meeting held on 08.04.2022.

At the meeting, the Committee further noted that the formulation 'Sitagliptin' is on the verge of becoming off-patent. The Committee at recent Multidisciplinary Committee of Experts meeting noted that seventeen applications have been received for retail price fixation of four Fixed Dose Combinations (FDCs) of Sitagliptin and Metformin tablets.

50% haircut on Patent Price-

The Authority noted that the formulation "Sitagliptin" has become/ is on the verge of becoming off-patent and observed that, in line with the decision taken in its 89th meeting dated 28.06.2021, if the calculation is based on six-month prior market data, the price of the patented period would be taken into consideration and hence the price rationalisation due to the expiry of the patent may not pass on to the patients.

(ii)The Authority further noted that the matter was placed before the 40th meeting of the Multidisciplinary Committee of Experts held on 14.03.2022 which in line decision taken in the 89th Authority meeting dated 28.06.2021, recommended to fix the retail price as per the following methodology

"....The Committee observed that the market data of the FDCs of Sitagliptin and Metformin tablet is also available and noted that if the retail price is calculated based on six month prior market data, the price of the patented period would be taken into consideration, and the benefit of price reduction due to medicines which has become/ is on the verge of becoming off-patent would not pass not on to the consumers. The Committee deliberated upon the matter in detail and is of the opinion that the price of drugs be reduced in respect of the drugs which has become/ on the verge of becoming off-patent so as to pass the benefit of price reduction to the consumers and that a reduction of 50% be allowed on the patented component of FDCs i.e. `Sitagliptin' to arrive at the retail price. Accordingly, the Committee recommended to allow retail price for the FDCs of Sitagliptin and Metformin tablet in line with the decision taken in its 33rd meeting held on 21.06.2021. However, where the calculated retail price of the FDC of formulation based on six-month prior market data as per the provisions of DPCO 2013 is lower than claimed price and the calculated price, the Committee recommended that the same would be allowed."

Accordingly , the Committee recommended the retail price of FDCs of Sitagliptin + Metformin Hydrochloride IP tablet for various companies including Alkem Healthsciences, Alkem Laboratories, Exemed Pharma, Emcure Pharma, Zydus Healthcare, Morepen Labs


Sl. No.

Name of the Formulation / Brand Name

Strength

Unit

Manufacturer & Marketing Company

Retail Price (Rs.)

4(xxx)a

Sitagliptin Phosphate+Metformin Hydrochloride Tablet

Each film coated tablet contains:

Sitagliptin Phosphate Monohydrate IP 64.25mg is eq. to Sitagliptin 50 mg Metformin Hydrochloride IP 1000mg

1 tablet

M/S Alkem Healthsciences (A Unit of Alkem Laboratories Ltd.) /M/S Alkem Laboratories Limited

20.02 (Note 7)

4(xxx)b

Sitagliptin Phosphate+Metformin Hydrochloride Tablet

Each film coated tablet contains:

Sitagliptin Phosphate Monohydrate IP 64.25mg is eq. to Sitagliptin 50 mg Metformin Hydrochloride IP 500mg

1 tablet

M/S Alkem Healthsciences (A Unit of Alkem Laboratories Ltd.) /M/S Alkem Laboratories Limited

18.34 (Note 7)

4(xxx)c

Sitagliptin Phosphate+Metformin Hydrochloride(Extended Release) Tablet

Each film coated bilayered tablet contains:

Sitagliptin Phosphate eq. to Sitagliptin 100 mg Metformin Hydrochloride IP 500mg (As an extended release form)

1 tablet

M/S Alkem Healthsciences (A Unit of Alkem Laboratories Ltd.) /M/S Alkem Laboratories Limited

20.17(Note 7)

4(xxx)d

Sitagliptin Phosphate+Metformin Hydrochloride(Extended Release) Tablet

Each film coated bilayered tablet contains:

Sitagliptin Phosphate eq. to Sitagliptin 100 mg Metformin Hydrochloride IP 1000mg (As an extended release form)

1 tablet

M/S Alkem Healthsciences (A Unit of Alkem Laboratories Ltd.) /M/S Alkem Laboratories Limited

19.81(Note 7)

4(xxx)e

Sitagliptin Phosphate+Metformin Hydrochloride Tablet

Each film coated tablet contains:

Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg Metformin Hydrochloride IP 500mg

1 tablet

M/S Exemed Pharmaceuticals / M/s Emcure Pharmaceuticals Limited

18.

34 (Note 7)

4(xxx)f

Sitagliptin Phosphate+Metformin Hydrochloride Tablet

Each film coated tablet contains:

Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg Metformin Hydrochloride IP 1000mg

1 tablet

M/S Exemed Pharmaceuticals / M/s Emcure Pharmaceuticals Limited

20.02(Note 7)

4(xxx)g

Sitagliptin +Metformin Hydrochloride Tablet

Each film coated tablet contains:

Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg Metformin Hydrochloride IP 500mg

1 tablet

M/S Zydus Healthcare Limited

18.34 (Note 7)

4(xxx)h

Sitagliptin +Metformin Hydrochloride Tablet

Each film coated tablet contains:

Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg Metformin Hydrochloride IP 1000mg

1 tablet

M/S Zydus Healthcare Limited

20.2 (Note 7)

4(xxx)i

Sitagliptin +Metformin Hydrochloride Tablet

Each film coated tablet contains:

Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg Metformin Hydrochloride IP 500mg

1 tablet

M/S Morepen LaboratoriesLimited

18.34(Note 7)

4(xxx)j

Sitagliptin +Metformin Hydrochloride Tablet

Each film coated tablet contains:

Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg Metformin Hydrochloride IP 1000mg

1 tablet

M/S Morepen Laboratories Limited

20.2 (Note 7)


Also Read:Cipla gets CDSCO panel okay to manufacture, market Metformin, Sitagliptin FDC



MetforminSitagliptinnppasun pharmamankindlupinsitagliptin tablets
Meghna A Singhania
Meghna A Singhania

Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She is a member of the Association of Healthcare Journalists. She can be contacted at meghna@medicaldialogues.in. Contact no. 011-43720751

Show Full Article
Next Story

Editorial

Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

Relevance of Pioglitazone in Indian T2DM Care Continuum

Relevance of Pioglitazone in Indian T2DM Care Continuum

Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

View All

Journal Club Today

Study Reveals Why Your Immune System Works Better in Daylight

Study Reveals Why Your Immune System Works Better in Daylight

View All

Health News Today

Health Bulletin 30/May/2025

Health Bulletin 30/May/2025

View All
© 2022 All Rights Reserved.
Powered By: Hocalwire
X
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok